| Computing the social brain connectome across systems and states D Alcalá-López, J Smallwood, E Jefferies, F Van Overwalle, K Vogeley, ... Cerebral cortex 28 (7), 2207-2232, 2018 | 174 | 2018 |
| Building blocks of social cognition: Mirror, mentalize, share? D Alcalá-López, K Vogeley, F Binkofski, D Bzdok Cortex 118, 4-18, 2019 | 77 | 2019 |
| 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth … J Cortes, JM Pérez-García, M Ruiz-Borrego, A Stradella, B Bermejo, ... Journal of Clinical Oncology 41 (17_suppl), LBA506-LBA506, 2023 | 18 | 2023 |
| Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR [+])/human epidermal growth factor receptor … A Llombart-Cussac, C Harper-Wynne, A Perello, A Hennequin, ... Journal of Clinical Oncology 41 (16_suppl), 1001-1001, 2023 | 17 | 2023 |
| 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast … JM Pérez-García, J Cortés, M Ruiz-Borrego, M Colleoni, A Stradella, ... The Lancet 403 (10437), 1649-1659, 2024 | 5 | 2024 |
| Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study Cancers 14 (5880), 2022 | 5 | 2022 |
| Phase II study of the efficacy of retifanlimab (Rf)(INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis. X Garcia del Muro, MA Cuellar, P Maroto-Rey, P Giannatempo, ... Journal of Clinical Oncology 41 (16_suppl), 5043-5043, 2023 | 2 | 2023 |
| Decoding social knowledge in the human brain D Alcalá-López, D Soto bioRxiv, 2020.08. 18.255513, 2020 | 2 | 2020 |
| Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study XG Del Muro, DP López-Bravo, MA Cuéllar-Rivas, P Maroto, ... European Urology Oncology, 2024 | | 2024 |
| Abstract PO1-20-02: MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor … A Llombart-Cussac, JM Pérez-García, M Gion, D Alcalá-López, ... Cancer Research 84 (9_Supplement), PO1-20-02-PO1-20-02, 2024 | | 2024 |
| Abstract PS11-05: Trastuzumab Deruxtecan in patients with HER2 [+] or HER2-Low Advanced Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis: Results from … MV Batista, JM Pérez-García, L Garrigós, JÁ García-Sáenz, ... Cancer Research 84 (9_Supplement), PS11-05-PS11-05, 2024 | | 2024 |
| Abstract PS16-02: Efficacy and safety of first-line atezolizumab+ bevacizumab+ paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial M Gion, P Cortez-Castedo, I Blancas, A Cortés, F Marmé, S Blanch, ... Cancer Research 84 (9_Supplement), PS16-02-PS16-02, 2024 | | 2024 |
| 260P LUZERN: Phase II trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancer S Blanch, J Balmaña, LL Roso, JÁG Saenz, EF Vegas, ... ESMO Open 9, 2024 | | 2024 |
| Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial A Llombart-Cussac, JM Pérez-Garcia, MR Borrego, P Tolosa, S Blanch, ... Eclinicalmedicine 71, 2024 | | 2024 |
| Brain wide representation of social knowledge D Alcala-López, N Mei, P Margolles, D Soto PsyArXiv, 2023 | | 2023 |
| A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer M Sampayo-Cordero, B Miguel-Huguet, A Malfettone, E López-Miranda, ... Frontiers in Oncology 13, 2023 | | 2023 |
| Physiopy: A community-driven suite of tools for physiological recordings in neuroimaging KL Bottenhorn, D Alcalà-Lopez, A Ayyagari, MG Bright, ... | | |
